TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
Location: United States, Massachusetts, Cambridge
Member count: 51-200
Total raised: $125M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | Syno Capit... | synocapita... |
| - | 6 Dimensio... | 6dimension... |
| - | Curative V... | curativeve... |
| - | BioImpact ... | bioimpactc... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 21.03.2018 | Series B | $125M | - | finsmes.co... |
Mentions in press and media 7
| Date | Title | Description | Category | Author | Source |
| 20.01.2021 | TCR² Thera... | - | - | - | mpmcapital... |
| 31.12.2018 | Next-gen T... | Patrick Baeuerle Patrick Bae... | Financing | Natalie Gr... | endpts.com... |
| 22.03.2018 | Term Sheet... | THE VC WAR CHEST Good morning... | - | - | fortune.co... |
| 21.03.2018 | TCR2 Thera... | CAMBRIDGE, MA, Immuno-oncolo... | - | - | vcnewsdail... |
| 21.03.2018 | MPM Portfo... | - | - | - | mpmcapital... |
| 21.03.2018 | TCR2 Thera... | TCR2 Therapeutics Inc., an imm... | - | - | citybizlis... |
| 21.03.2018 | TCR2 Thera... | TCR2 Therapeutics Inc., a Camb... | USA | - | finsmes.co... |